Abstracts tagged "ANCA"

Abstract Number: 2731 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital
Shilpa Arora¹, Ambrish Athavale² and Peter Hart², ¹Medicine, John H Jr Stroger Hospital of Cook County, Chicago, IL, ²John H Jr Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis (RLV). We aimed to study the clinical features…
Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
John L. Niles¹, Peter A. Merkel², Lester Mertz³, Patricia B. Lehane⁴, Pooneh Pordeli⁵ and Félix Erblang⁶, ¹Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ⁶Hoffmann-La Roche Ltd., Basel, Switzerland
Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
Abstract Number: 2732 • 2018 ACR/ARHP Annual Meeting
Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center
Mehmet Nedim Taş¹, Mete Kara¹, Sertaç Ketenci¹, Mete Pekdiker², Raika Durusoy³, Fikret Bademkıran⁴, Gokhan Keser⁵ and Kenan Aksu⁵, ¹Rheumatology, Ege University Medical Faculty, izmir, Turkey, ²Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, ³Public Health, Ege University Medical Faculty, izmir, Turkey, ⁴Neurology, Ege University Medical Faculty, izmir, Turkey, ⁵Rheumatology, Ege University Medical Faculty, Izmir, Turkey
Background/Purpose: Among many other organs and systems, ANCA-associated vasculitis (AAV) may also affect nervous system in up to more than half of patients, resulting in…
Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Rona Smith¹, Rachel Jones², Ulrich Specks³, Carol A McAlear⁴, Kim Mynard², Simon Bond², David Jayne⁵ and Peter A. Merkel⁶, ¹Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ³Mayo Clinic College of Medicine, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting
Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Jun Ishizaki¹, Ayako Takemori², Koichiro Suemori¹, Takuya Matsumoto¹, Yoko Akita¹, Masaki Yasukawa¹, Nobuaki Takemori² and Hitoshi Hasegawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan
Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Priya Chokshi¹, Olufemi Aina², Naveed Masani², Melissa Fazzari³, Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Tobin Abraham⁴, Daniil Shimonov⁴, Zinal Patel⁴ and Steven E. Carsons¹, ¹Rheumatology, NYU Winthrop Hospital, Mineola, NY, ²Nephrology, NYU Winthrop Hospital, Mineola, NY, ³Biostatistics, NYU Winthrop Hospital, Mineola, NY, ⁴Medicine, NYU Winthrop Hospital, Mineola, NY
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…
Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting
HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations
Aya Kawasaki¹, Fumio Hirano², Ken-ei Sada³, Shigeto Kobayashi⁴, Hidehiro Yamada⁵, Hiroshi Furukawa¹, Kenji Nagasaka⁶, Takahiko Sugihara⁷, Kunihiro Yamagata⁸, Takayuki Sumida⁹, Shigeto Tohma¹⁰, Shoichi Ozaki⁵, Seiichi Matsuo¹¹, Hiroshi Hashimoto¹², Hirofumi Makino¹³, Yoshihiro Arimura¹⁴, Masayoshi Harigai¹⁵ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁵Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁷Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁸Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁹Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹⁰Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹¹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹²Juntendo University School of Medicine, Tokyo, Japan, ¹³Okayama University Hospital, Okayama, Japan, ¹⁴First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁵Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…
Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Qin Huang¹, Hao Ren¹, Yaping Zhan², Shenyi Yu² and Min Yang¹, ¹Department of Rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China, ²Department of rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…
Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Kimberly Morishita¹, Audrea Chen², Cherry Mammen¹, Angelyne Rivera³ and David Cabral¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Medicine, University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting
Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?
Valeria Scaglioni¹, Marina Scolnik², Florencia Pierini², Luis J. Catoggio³, Silvia Beatriz Christiansen⁴, Carlos Federico Varela⁵, Gustavo Greloni⁵, Guillermo Rosa-Diez⁵ and Enrique R Soriano⁶, ¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, CABA, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Nephrology Service. Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…
Abstract Number: 1289 • 2017 ACR/ARHP Annual Meeting
Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study
Angelyne Rivera¹, Kimberly Morishita², David Cabral² and Raashid Luqmani³, ¹Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Classification of chronic vasculitis to clinically or etiologically meaningful groups has been challenging. In 2008, the 1990 ACR classification criteria for GPA was adapted…
Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting
New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis
Alina Casian¹, Rachel Jones², Ruzaika Cader³, Alan D. Salama⁴, Shirish Sangle⁵, David Jayne⁶ and David P. D'Cruz⁷, ¹Lupus Unit, Guy's Hospital, London, United Kingdom, ²Nephrology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Nephrology, Norfolk and Norwich Hospitals, Norfolk, United Kingdom, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁶Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…
Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Alvise Berti^1,2, Eric L. Matteson^3,4, Cynthia S. Crowson^5,6, Ulrich Specks⁷ and Divi Cornec^8,9, ¹Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Department of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Division of Epidemiology, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁷Mayo Clinic College of Medicine, Rochester, MN, ⁸Department of Rheumatology, Brest Teaching Hospital, Brest, France, ⁹Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…
Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].